AOD-9604
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
AOD-9604 is a narrow fat-loss adjunct for targeted lipolysis without IGF-1 elevation, anabolic signaling, or endocrine disruption; its use case is modest fat-mobilization support, not standalone obesity treatment.
Clean safety profile across 900+ trial participants with no serious adverse events — but the Phase 2b clinical failure means fat loss efficacy is unproven under rigorous controlled conditions.
AOD-9604 is a narrow fat-loss adjunct for targeted lipolysis without IGF-1 elevation, anabolic signaling, or endocrine disruption; its use case is modest fat-mobilization support, not standalone obesity treatment.
Main risks are mild injection-site redness or welts, nonresponse, and overestimating efficacy; the Phase 2b trial failed to separate from placebo under rigorous diet-and-exercise controls.
Best fit is a low-hormone-burden fat-loss adjunct for users already in a deficit and active routine, especially when GLP-1 intolerance or GH-secretagogue stacking makes a cleaner lipolysis tool attractive.
Modest and protocol-dependent: roughly 5-6 lb additional fat loss over 12 weeks is the optimistic practical read, with slow onset around weeks 4-6 and wide responder variation.
Do not use AOD-9604 expecting anabolic, healing, or anti-aging effects — it has a single mechanism (β3-AR lipolysis) and produces nothing outside the fat-burning domain.
Intro
AOD-9604 (Anti-Obesity Drug 9604, CAS 221231-10-3, also known as Tyr-hGH177-191) is a synthetic peptide derived from human growth hormone.
It spans amino acids 177–191 of the GH C-terminus and is modified with an N-terminal tyrosine residue for metabolic stability. Molecular weight: approximately 1815 g/mol. It differs from HGH Fragment 176-191 by this single tyrosine substitution.
Developed at Monash University (Melbourne, Australia) by Frank M. Ng and colleagues in the late 1990s, AOD-9604 was designed to isolate the fat-mobilizing domain of GH without the blood sugar disruption, muscle growth, or IGF-1 elevation associated with full GH therapy. Metabolic Pharmaceuticals Pty Ltd licensed the compound for pharmaceutical development. Six randomized double-blind placebo-controlled clinical trials were conducted.
The clinical history is the central context for this compound. Phase 2a (approximately 300 obese adults, oral 1 mg/day, 12 weeks, no strict dietary controls): approximately 2.6–2.8 kg additional fat loss versus placebo — a positive signal that advanced development. Phase 2b (536 subjects, oral 1 mg/day, 24 weeks, with strict diet and exercise controls): FAILED to demonstrate statistically significant weight loss versus placebo. The NDA application was subsequently withdrawn and the compound repositioned as a nutraceutical ingredient. FDA GRAS (Generally Recognized As Safe) status was obtained in 2014 as a food supplement ingredient — a safety designation that does not imply efficacy, commonly misrepresented by community sources as a form of FDA approval. The FDA has additionally proposed excluding AOD-9604 from the compounding bulk drug substances list, which would restrict US compounding pharmacy availability.
WADA classifies AOD-9604 as a banned performance-enhancing substance. No country has approved it as a pharmaceutical drug.
A critical interpretive gap explains the bifurcated community narrative: Phase 2a did not control lifestyle factors; Phase 2b did. The positive Phase 2a signal may only be detectable above an uncontrolled-lifestyle background — when lifestyle is equalized via strict controls, the modest lipolytic push becomes too small to separate statistically from placebo. Meanwhile, the community injectable protocol (200–600 mcg subQ, fasted, before activity) has never been tested in any RCT. The oral 1 mg/day route used in all clinical trials is different from the subQ route used by the community. Both the 'this compound failed' and 'it works when used correctly' narratives are simultaneously defensible because they describe different protocols under different conditions.
Observed Effects
The primary effect is fat loss — specifically mobilization of free fatty acids from adipose tissue.
β3-AR receptors are expressed highest in visceral and deep subcutaneous fat deposits, which are notoriously resistant to diet and exercise alone, providing some mechanistic basis for the community observation that it preferentially reduces stubborn regional fat.
Clinical trial data: Phase 2a showed approximately 2.6–2.8 kg additional fat loss over 12 weeks at 1 mg/day oral vs placebo. Phase 2b (536 subjects, 24 weeks, strict dietary controls) showed no statistically significant difference from placebo. Community reports: approximately 5–6 lbs additional fat loss over 12 weeks above baseline when the injectable fasted-cardio protocol is followed. This community figure likely reflects a selected population of responders and may not represent typical outcomes.
Onset is slow. The first month is typically silent — no visible changes despite adherence. Community reports and practitioner guides consistently note that results begin appearing at weeks 4–6. A 12-week minimum is required for meaningful assessment. Users who run only 4-week cycles typically conclude the compound is not working and do not reorder — incorrectly, if the protocol was otherwise correct.
A mild thermogenic sensation after injection is reported by a subset of users, consistent with β3-AR activation, which also drives adipose thermogenesis. Muscle mass is neither gained nor lost — AOD-9604 has no effect on IGF-1 or any anabolic hormone.
A real non-responder population exists. Community educators and practitioner reviewers explicitly acknowledge this: 'some people get fat loss out of AOD and some people don't — similar to HGH frag.' The likely explanation is β3-AR genetic polymorphism variance, known to affect response to other β3-AR agonists. Non-response is not a quality issue — it is pharmacogenomic. Users who see no change after proper adherence through weeks 6–8 are likely non-responders and should discontinue rather than escalate dose.
Expectation calibration: AOD-9604 produces effects only in the lipolytic domain. Users expecting BPC-157-style healing, GH-like muscle growth, anti-aging, or anabolic effects will be disappointed — the compound does exactly one thing.
Field Reports
The typical community timeline: month 1 is silent — no visible changes despite adherence. Users who expected rapid results often quit during this window, incorrectly concluding the compound is not working.
Results begin appearing at weeks 4–6, primarily in the abdominal region. Cumulative fat loss becomes measurable by weeks 8–12. A 12-week minimum is required for meaningful assessment; a 4-week run is almost certain to be inconclusive.
Quantitative reports: approximately 5–6 lbs of additional fat loss over 12 weeks above baseline when the injectable fasted-cardio protocol is correctly followed. One extended first-person account documented visible abdominal fat loss appearing at months 2-3, with injection site reactions in the early weeks that resolved. These community figures align directionally with the Phase 2a clinical result but come from a selected population of responders.
Injection site redness and mild welt formation is the most commonly reported acute side effect — transient (minutes to hours), not dangerous, consistent with local histamine response. A subset of users report a mild thermogenic sensation post-injection, consistent with β3-AR activation.
Non-responder variance is real and explicitly acknowledged by experienced practitioners: some users see meaningful fat loss, some see nothing. The compound's narrow mechanism (a single β3-AR pathway) and known β3-AR genetic polymorphism variance across the population make this expected. Users following correct protocol (fasted, before activity, 300–500 mcg/day subQ) who see no change by weeks 6–8 are likely non-responders and should stop rather than escalate dose or run longer.
Expectation failures are the most common source of user dissatisfaction. Because AOD-9604 is a GH fragment, some users expect BPC-157-style healing, GH-like muscle effects, or anti-aging properties. The compound does exactly one thing — lipolysis via β3-AR. Everything else is projection from the GH parentage.
Community Consensus
AOD-9604 has over two decades of community use predating the GLP-1 era — labeled 'the forgotten fat loss peptide.' Community interest rebounded in 2025-2026, driven by users seeking non-GLP-1 fat loss options (GLP-1 intolerance, preference for 'hormone-based' mechanisms, or desire to layer complementary mechanisms on top of existing GLP-1 therapy).
The community narrative bifurcates, and this tension is not easily resolved. The 'failed compound' camp correctly cites the Phase 2b clinical failure: a rigorous 536-subject trial with dietary controls found no significant weight loss vs placebo. The 'underrated compound' camp correctly notes that the failed trial used oral 1 mg/day without the fasted + activity protocol the community uses — and that no RCT has ever tested the injectable subQ protocol. Both narratives are simultaneously defensible because they describe different protocols tested under different conditions.
FDA GRAS status (2014) is widely cited by community sources as a regulatory credential. This is a misrepresentation. GRAS designates the compound as safe as a food ingredient — it is not an FDA approval, not an efficacy endorsement, and was self-submitted by the manufacturer. The FDA's concurrent proposal to exclude AOD from the compounding bulk drug list moves in the opposite regulatory direction. Clinician-facing sources explicitly flag that many sellers market AOD-9604 with claims that exceed what the evidence supports.
Community consensus on positioning: AOD-9604 is an adjunct, not a primary fat loss agent. The dominant use case is 'stubborn fat that won't budge despite diet and exercise' — the last-mile targeting framing. Rated 4/10 for fat loss efficacy relative to other compounds by community reviewers; B-tier in fat burner tier lists. The evidence gap relative to semaglutide or pharmaceutical GH is described as 'massive' in direct comparison articles.
Half-life discrepancy: rat in vitro plasma half-life is approximately 4 minutes (Moré & Kenley 2014); community in-human estimates range from 30 minutes to 2 hours for subQ administration, with an active duration of approximately 4 hours. Community timing recommendations are calibrated to these in-human estimates, not the rat data. WADA banned AOD-9604 and the compound has been identified in confiscated samples, confirming active community use as of the 2014 Cox et al. doping detection paper.
Risks & Monitoring
The most commonly reported side effect in first-person community reports is injection site redness and mild welt formation.
This is a transient local histamine response to the peptide or carrier, resolving within minutes to hours. Practical mitigation in reports centers on rotating sites and reassessing handling or product quality if reactions are unusually persistent.
Clinical trial data across six trials with 900+ participants found no serious adverse events directly attributed to AOD-9604 at studied doses. No significant effects on blood glucose, insulin, IGF-1, thyroid function, prolactin, cortisol, or lipid profiles were observed. Genotoxicity testing was negative across the Ames test, chromosomal aberration assay, and micronucleus test. The safety database is one of the compound's genuinely strong attributes — it was explicitly designed to isolate fat mobilization from the diabetogenic and growth-promoting effects of full GH, and this design goal was achieved.
Unlike full growth hormone (which causes insulin resistance at therapeutic doses), AOD-9604 produces no meaningful effects on insulin sensitivity. No androgenic effects, virilization, endocrine suppression, or HPG axis disruption. No long-term safety data beyond 24 weeks exists from clinical trials. Community use at injectable doses of 200–600 mcg/day has not been associated with serious adverse outcomes in available community reports, but formal long-term human safety data is absent.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Essential to assess compound response given the slow and modest effect. Without baseline measurement, users cannot distinguish compound response from natural weight fluctuation over a 12-week period.
AOD-9604 is not expected to affect glucose or insulin. Baseline values provide reassurance and detect pre-existing metabolic issues (e.g., insulin resistance) that would reduce the compound's lipolytic response.
At weeks 6-8 of a 12-week protocol, a body composition check helps identify non-responders before completing the full cycle. No measurable change by week 8 despite protocol adherence suggests low likelihood of meaningful response.
Avoid With
Do not combine AOD-9604 with the following. Sorted highest-severity first.
Why:Insulin directly antagonizes β3-AR-mediated lipolysis. Taking AOD in a post-meal, insulin-elevated state partially or fully suppresses the compound's mechanism of action. This is not a drug interaction — the compound is not dangerous post-meal, just functionally inactive.
What to do:Always administer fasted. This is a protocol constraint, not a safety concern. Fasted morning administration is the single most important protocol element.
Why:Potential β3-AR desensitization acceleration if multiple β3-AR agonists are co-administered continuously. Mirabegron is used off-label for fat loss via the same β3-AR pathway as AOD. Concurrent use may accelerate receptor downregulation, reducing the effectiveness of both over time.
What to do:No direct safety data on this combination. Theoretical pharmacological concern. If combining, consider alternating rather than simultaneous dosing.
Protocols By Goal
Stubborn fat adjunct (most validated use case): User is already in a caloric deficit with regular exercise, has plateaued on diet and exercise alone, and wants additional lipolytic push on stubborn visceral or deep subcutaneous fat. Protocol: 300–500 mcg subQ 30–60 min before fasted morning cardio, 12 weeks on, 4 weeks off. Physician first-person framing: 'stubborn fat that wouldn't budge despite diet and exercise.' β3-ARs are expressed highest in the visceral and deep subcutaneous fat deposits that are most resistant to conventional caloric restriction.
GH secretagogue adjunct (older users): For users already running CJC-1295/Ipamorelin or other GH secretagogues who want additional fat loss — especially older users where GH secretory capacity has declined. GH secretagogues drive GH pulse amplitude; AOD drives direct adipose lipolysis via a separate pathway with no mechanistic overlap. Take GH secretagogue at night; take AOD before morning fasted cardio.
GLP-1 agonist stack: Increasingly used alongside semaglutide, tirzepatide, or retatrutide. GLP-1 agonists handle appetite suppression and systemic metabolic effects via hypothalamic GLP-1R agonism; AOD provides additional direct lipolysis through β3-AR activation in peripheral adipose tissue. The mechanisms are complementary with no overlap. This combination appears in community protocol guides, but additive benefit is not validated.
Advanced GH + AOD double-window reports: Pharmaceutical GH before bed (overnight fat oxidation and GH pulse) + AOD 60 min before morning fasted cardio (morning lipolytic spike). This creates two distinct lipolytic windows. Described in community educator content as a 'double whammy synergistic effect.' An advanced protocol used in competitive settings but without structured trial validation.
Dosing Details
Observed injectable dose: community protocols commonly discuss 300-500 mcg/day subcutaneously, with conservative starts around 200-300 mcg/day for 2-4 weeks to assess individual response. These are observed-use ranges, not approved clinical dosing instructions.
Timing is mechanistically important in community practice: 30-60 minutes before fasted morning activity is the dominant pattern because insulin elevation may suppress beta-3-adrenergic lipolysis. Afternoon or evening administration before activity is also reported, but with less community confidence than fasted morning timing.
Route: subcutaneous injection is the community-standard route, with some intramuscular reports. Preparation mechanics are not standardized and should not be treated as reader-specific injection guidance. No oral dose has community-validated efficacy after the trial oral route failed.
Cycle length: 8-16 weeks is commonly cited, with 12 weeks the most common assessment window. The off period is framed around beta-3-AR desensitization theory; no endocrine suppression occurs and no PCT is required.
Split dosing: some protocols use half the daily dose before morning fasted cardio and half before afternoon training to capture two activity-window lipolytic events per day. No validated additive benefit data exists for split dosing.
Common reported mistakes: taking it with or after a meal, not doing activity during the active window, running only 4-week cycles before the 4-6 week onset window, and expecting effects beyond lipolysis.
Stacks & Alternatives
Complementary non-overlapping mechanisms: GLP-1s suppress appetite via hypothalamic GLP-1R agonism; AOD drives peripheral adipose lipolysis via β3-AR activation. Adding AOD to a GLP-1 protocol provides additional lipolytic mechanism without redundancy. Explicitly recommended in community protocol guides as a combined approach for greater fat loss results.
GH secretagogues increase endogenous GH pulse amplitude; AOD adds direct β3-AR lipolysis via a separate pathway with no mechanistic overlap. Particularly useful for older users whose GH secretory capacity has declined, where secretagogues alone produce less fat loss. Take GH secretagogues at night; take AOD before morning fasted cardio.
GH before bed for overnight fat oxidation and systemic GH effects; AOD 60 minutes before morning fasted cardio for a morning lipolytic spike. Creates two distinct lipolytic windows. Described as a synergistic 'double whammy' in community educator content. Advanced protocol used in competitive settings without structured trial validation.
The direct chemical predecessor, functionally similar in community practice via the same β3-AR mechanism. Both are B-tier for fat loss. Community educators recommend experimenting with both to determine individual response. Stacking both provides little additional benefit over either alone — use one or the other based on availability and individual response.
Some community protocols layer AOD-driven lipolysis with mitochondrial peptides to theoretically enhance fatty acid oxidation capacity — combining fat mobilization (AOD) with improved mitochondrial ability to burn the mobilized FFAs. No trial data supports this combination specifically; mechanistic rationale exists but remains speculative.
Alternatives
Stack Cost
Low tax: AOD-9604 mostly consumes injection logistics, timing discipline, sourcing judgment, and realistic outcome tracking rather than endocrine, glucose, or organ-monitoring capacity.
The article's dosingProtocols involve subQ injection, storage/handling constraints, and a fasted pre-activity window. The main practical burden is route, timing, and handling rather than systemic toxicity.
recommendedPanels focuses on body-composition tracking, with optional fasting glucose and insulin because the article notes AOD-9604 is not expected to affect glucose, insulin, IGF-1, thyroid, cortisol, or lipids.
The practicalConsiderations section says injectable lyophilized powder is the community-standard form, oral capsules lack validated community efficacy, and proposed FDA compounding exclusion may affect US availability.
- ·Does not occupy a GH/IGF lane because the article repeatedly notes no IGF-1 elevation, no endocrine suppression, and no GH-like anabolic effect.
- ·Counts as a fat-loss activity-window layer, not a standalone weight-loss engine; it fits best under an existing diet, activity, GLP-1, GH-secretagogue, or GH protocol when expectations are modest.
- ·Do not stack casually with other beta-3 adrenergic agonists; stackingConflicts flags possible receptor desensitization and reduced effectiveness over time.
- ·Do not use it as the primary intervention when appetite control is the real bottleneck; the article positions GLP-1 agonists as much stronger for systemic weight loss.
- ·SubQ route, clean handling expectations, and refrigerated storage.
- ·Fasted administration 30-60 minutes before activity, with protocol discipline around meals and exercise.
- ·Baseline and follow-up body-composition tracking because the expected effect is modest and slow.
- ·A planned stop point by weeks 6-8 if adherence is correct and no measurable response appears.
- ·Sourcing diligence for lyophilized injectable product, since oral products do not match the community protocol discussed in the article.
The systemic safety tax is low, but the user still needs peptide reconstitution, subQ injection, fasting/activity timing, and enough measurement discipline to avoid mistaking slow onset for failure.
- ·Unwilling to inject or handle lyophilized peptides
- ·Expecting appetite suppression, anabolic effects, healing, or anti-aging effects
- ·Unable to keep administration fasted and tied to activity
- ·Subject to WADA testing or strict sport rules
The article states no endocrine suppression occurs and no PCT is required. Stopping mainly means the incremental lipolytic push disappears, not that a recovery protocol is needed.
- ·Loss of the small added fat-loss push
- ·Unresolved non-response if the user never reached the 6-8 week assessment window
- ·Return to baseline fat-loss pace if diet and activity remain unchanged
The article identifies post-meal dosing, no activity during the active window, and stopping at 4 weeks as main failure causes; keep dosing fasted before activity and reassess at weeks 6-8.
The article treats non-response as real and likely pharmacogenomic; discontinue rather than escalating dose or extending indefinitely.
Rotate sites and reassess product handling if reactions are unusually severe or persistent.
The article positions AOD-9604 as a modest adjunct with a failed controlled Phase 2b trial; choose stronger interventions when appetite, adherence, or total weight loss is the bottleneck.
womenConsiderations marks pregnancy contraindicated by default because AOD-9604 is unapproved and reproductive safety data are absent.
The article's legalStatus and communityContext state AOD-9604 is WADA-banned and has been detected in confiscated samples.
observedEffects and similarCompounds state AOD-9604 is modest, slow, and far weaker than GLP-1 agonists; using it as the main intervention creates opportunity cost.
The practical burden is mostly route and handling; injection-site reactions are the common adverse event, and contaminated or mishandled product changes the risk profile.
Practical Setup
Route and handling: the injectable formulation is the community-standard form, but preparation mechanics and sterile technique are not standardized and should not be treated as reader-specific injection guidance.
Product quality varies across research-compound channels; oral capsules have no validated community protocol after the clinical trial oral route failed. Promotional and access-route details are intentionally omitted.
Storage and quality: peptide stability depends on temperature, handling, and product quality. Users should treat unusual reactions or degraded-looking product as a quality problem rather than a reason to escalate dose.
Biomarkers to track: no specific bloodwork monitoring is required given the clean safety profile across clinical trials. Practical tracking recommended: body weight weekly, waist circumference or progress photos at baseline and every 4 weeks. Users with pre-existing metabolic conditions should maintain their usual monitoring schedule - AOD-9604 does not affect glucose, insulin, or lipid panels.
Protocol discipline is the primary determinant of outcome. The most common errors explaining "it didn't work": taking it with or after a meal, not doing activity during the active window, running only 4-week cycles before the 4-6 week onset window, or expecting effects outside the lipolytic domain. Users following the observed fasted + activity pattern who still see no change by week 8 are likely non-responders and should not escalate.
Mechanism Deep Dive
AOD-9604 stimulates lipolysis via the β3-adrenergic receptor (β3-AR) pathway. β3-AR activation triggers hormone-sensitive lipase (HSL), which hydrolyzes stored triglycerides in adipose tissue to release free fatty acids (FFAs) into circulation. This mechanism was established definitively in β3-AR knockout mouse studies (Heffernan, Ng et al., Endocrinology 2001): both hGH and AOD-9604 lost their fat-reducing efficacy entirely in knockout animals, confirming β3-AR as the obligatory mediator. AOD-9604 also inhibits lipogenesis — the de novo synthesis of new fat — giving it a dual action: stimulate fat breakdown and impair fat storage simultaneously.
A key mechanistic insight distinguishing AOD from full growth hormone: 1 mg of AOD-9604 (or HGH Fragment 176-191) represents the same C-terminal receptor binding as approximately 8–9 IU of growth hormone at the lipolytic domain. Yet AOD does not produce fat loss equivalent to 8–9 IU of GH. The limiting factor is IGF-1: full growth hormone produces fat loss through multiple pathways including IGF-1-mediated nutrient partitioning, skeletal muscle fatty acid uptake, overnight metabolic rate elevation, and direct GH receptor-mediated adipolysis. AOD-9604, lacking IGF-1 stimulation, has only the direct β3-AR pathway — explaining why equivalent C-terminal binding yields proportionally less fat loss than a full GH dose.
The activity-window dependency is mechanistically obligatory, not optional. AOD mobilizes FFAs from adipose tissue into circulation. These FFAs must then be oxidized through aerobic metabolism during the compound's active window. If the user is sedentary after administration, liberated FFAs re-esterify back into triglycerides in adipose tissue and no net fat loss occurs. Similarly, insulin directly inhibits β3-AR-mediated lipolysis — taking AOD in a post-meal, insulin-elevated state partially or fully suppresses the mechanism. Taking it fasted, before activity, is not a recommendation but a functional prerequisite.
Pharmacoketics: plasma half-life approximately 4 minutes in rat plasma in vitro (Moré & Kenley 2014); community in-human estimates are 30 minutes (subQ conservative) to 2 hours (subQ extended), with active duration of approximately 4 hours. Metabolism proceeds by sequential N-terminal amino acid truncation. In-human injectable pharmacokinetic data has not been published — all clinical PK studies used the oral route. AOD-9604 does not affect blood glucose, insulin, IGF-1, GH secretion, testosterone, estrogen, thyroid function, cortisol, or any endocrine axis. No post-cycle therapy is required.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Phase 2a showed approximately 2.6-2.8 kg additional fat loss versus placebo over 12 weeks at oral 1 mg/day.
This positive signal should not be transferred directly to the community injectable fasted-cardio protocol or to users already under strict diet and exercise control.
Phase 2b enrolled 536 subjects for 24 weeks at oral 1 mg/day with strict diet and exercise controls and failed to show statistically significant weight loss versus placebo.
This is the central efficacy caveat: the controlled oral trial failed, so community injectable claims remain unvalidated by RCT evidence.
Six randomized double-blind placebo-controlled clinical trials were conducted.
The six-trial safety base supports tolerability claims better than it supports the community injectable efficacy protocol.
Community reports describe approximately 5-6 lbs additional fat loss over 12 weeks when the injectable fasted-cardio protocol is followed.
This is responder-biased community evidence, not a controlled outcome estimate; non-responders and failed short cycles are common in the article.
Results typically begin appearing at weeks 4-6, with a 12-week minimum required for meaningful assessment.
The timing rule is practical community guidance rather than a trial-validated onset curve.
Clinical trial data across six trials with 900+ participants found no serious adverse events directly attributed to AOD-9604 at studied doses.
This supports short-to-medium-term tolerability in studied settings; it does not prove long-term injectable gray-market safety.
Standard injectable dose is 300-500 mcg/day subcutaneously, with conservative starts at 200-300 mcg/day for 2-4 weeks.
The article explicitly distinguishes this untested injectable protocol from the oral route used in pivotal trials.
Cycle length is commonly 12 weeks on and 4 weeks off, with a total community-cited range of 8-16 weeks.
The 4-week off period is framed around beta-3-AR desensitization theory, not endocrine recovery or controlled trial evidence.
500 mcg/day is a common community example; preparation math is intentionally not provided.
This is arithmetic and handling guidance, not efficacy evidence; errors here affect dose accuracy and contamination risk.
Plasma half-life is approximately 4 minutes in rat plasma in vitro; community in-human estimates range from 30 minutes to 2 hours subQ with active duration around 4 hours.
Published PK and community timing estimates should not be conflated; the article notes human injectable PK has not been published.
Storage guidance commonly emphasizes refrigeration and avoiding degraded prepared product.
This is handling guidance rather than a clinical outcome claim; it matters because sourcing and storage are part of AOD-9604's practical tax.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.